Latest Breaking News On - School of oncology - Page 1 : vimarsana.com

Study provides new insight on how HER2-low tumors may evolve in breast cancer patients

Study provides new insight on how HER2-low tumors may evolve in breast cancer patients The finding that breast tumors can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumors. The first study of its kind exploring how breast cancers change from the primary to the recurrent tumor has revealed that nearly 30% of breast cancer patients convert from, or to, human epidermal growth factor receptor (HER)2-low status. Specifically, the study found that 14% of triple-negative breast cancers with HER2-negative expression (also referred to as HER2-0) in the primary tumor converted to HER2-low expression in the recurrent tumor possibly offering an option to such hard-to-treat tumors.

Switch of breast tumors to HER2-low might provide greater therapeutic options

Switch of breast tumors to HER2-low might provide greater therapeutic options ANI | Updated: May 09, 2021 18:56 IST Lugano [Switzerland], May 9 (ANI): The finding that breast tumours can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumours. The first study of its kind exploring how breast cancers change from the primary to the recurrent tumour has revealed that nearly 30% of breast cancer patients convert from, or to, human epidermal growth factor receptor (HER)2-low status. The study was published in the journal Annals of Oncology.

Switch of breast tumors to HER2-low in recurrence may provide greater therapeutic options

European Society for Medical Oncology The finding that breast tumours can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumours. The first study of its kind exploring how breast cancers change from the primary to the recurrent tumour has revealed that nearly 30% of breast cancer patients convert from, or to, human epidermal growth factor receptor (HER)2-low status. Specifically, the study found that 14% of triple-negative breast cancers with HER2-negative expression (also referred to as HER2-0) in the primary tumour converted to HER2-low expression in the recurrent tumour possibly offering an option to such hard-to-treat tumours.

Escola de Oncologia dos PALOP está a nascer

Moodle.org: Moodle jobs

Type: Contract Location: Based on site (the Christie trust) with opportunity for home working (can be discussed at interview) The Christie School of Oncology provides specialist education programmes at the largest single-site cancer centre in Europe and one of the top-rated cancer hospitals worldwide.  A rare opportunity for a talented and creative learning development specialist has arisen within our Digital Learning team, to support the increased demand for the team’s high quality services. You will play an important role within our expanding professional team, leading end-to-end production of multiple projects involving utilisation of specialist learning development software.  You will be a highly motivated individual with the ability to hit the ground running. You will have expertise in all aspects of learning development, including virtual learning environment managements, educational development and graphic design.

Director of School of Oncology job with The Christie NHS Foundation Trust